- Atlas
- Medicine & Health
- Hematology
Hematology
Hematology is the branch of internal medicine that studies blood—its cells, its plasma, and the proteins that make it clot—and the diseases that arise when any of these go wrong.
12 frameworks, from 150 to today · Internal Medicine · Medicine & Health
- Humorism 150-1800
- Quantitative hematology 1850-Present
- Morphological hematology 1870-Present
- Bone marrow as source paradigm 1900-Present
- Transfusion medicine and blood banking 1900-Present
- Bone marrow examination 1940-Present
- Combination chemotherapy 1955-Present
- Molecular and cytogenetic hematology 1960-Present
- Coagulation 1964-Present
- Hematopoietic stem cell transplantation 1968-Present
- Immunophenotyping 1975-Present
- Cellular immunotherapy 2011-Present
Overview
Hematology is the branch of internal medicine that studies blood—its cells, its plasma, and the proteins that make it clot—and the diseases that arise when any of these go wrong1. Its practitioners diagnose and treat anemias, bleeding disorders such as hemophilia, abnormal clotting such as thrombosis, and cancers of the blood and bone marrow such as leukemia and lymphoma1. They also run blood banks and transfusion services, and they manage the most intensive treatments in medicine, including bone marrow transplantation and engineered immune cells. What is at stake is unusually direct: blood is the tissue that carries oxygen, defends against infection, and seals its own leaks, so when it fails, the whole body fails. The history of hematology is the story of how physicians learned to see what blood is made of, to count and classify its parts, to replace them, to understand the chemistry of clotting, and finally to attack and reprogram the cells that make them.
Ancient Humors and the Long Reign of Bloodletting
For more than two thousand years, the dominant theory of blood in European and Islamic medicine was humoralism, inherited from Greek physicians and systematized by Galen in the second century CE. Health was thought to depend on the balance of four bodily fluids—blood, phlegm, yellow bile, and black bile—and disease on their imbalance23. Blood was the warm, moist humor, and excess blood was treated by bloodletting, often by opening a vein. This was not a random practice: it followed from a coherent physiology, and it was taught in medical schools from Alexandria to Baghdad to Salerno. The theory's weakness was that it explained everything and predicted little; it could not distinguish one anemia from another or one bleeding disorder from another. Its long dominance meant that for centuries the observable properties of blood—its color, its tendency to clot in a cup, its separation into a dark clot and a pale serum—were interpreted within humoral categories rather than studied as objects in their own right.
Seeing the Cells: Morphology and the Microscope
The decisive break came with the microscope. In the seventeenth century, Antony van Leeuwenhoek described "red globules" in blood, and by the eighteenth and nineteenth centuries microscopists could see that blood contained several kinds of particles45. The key figure in morphological hematology—the study of blood cells by their appearance—was Paul Ehrlich, who in the 1870s and 1880s developed staining techniques that made different white blood cells distinguishable by the dyes they took up. Ehrlich's triacid and other stains revealed that leukocytes were not a single population but several lineages, and he named them by their staining behavior: neutrophils, eosinophils, basophils, lymphocytes. This mattered because it turned the blood into a readable tissue. A physician could now look at a stained smear and say not just "the blood is diseased" but which cell line was overproduced or missing.
The morphological tradition reached its height in the description of the anemias. In the nineteenth century, clinicians separated the pallor and weakness of anemia into distinct types by examining the size and color of red cells. The terms microcytic (small cells), macrocytic (large cells), and normocytic (normal-sized cells) became diagnostic categories, and the recognition that some anemias were caused by iron deficiency while others followed a dietary deficiency—pernicious anemia, later linked to vitamin B12—showed that morphology could point to cause. Sickle cell disease was described morphologically in 1910 by James Herrick, who saw the characteristic elongated cells in a dental student's blood; the underlying molecular defect would not be explained for another four decades.
Counting and Measuring: Quantitative Hematology
Morphology told you what cells looked like; quantitative hematology told you how many there were. Manual counting chambers, such as the hemocytometer, allowed nineteenth-century physicians to estimate cell concentrations, and the invention of the hemoglobinometer gave a measure of the blood's oxygen-carrying pigment. But the great transformation came in the mid-twentieth century with automated cell counting. The Coulter principle, developed by Wallace Coulter in the 1950s, measured cells by passing them through a small aperture and detecting changes in electrical impedance; the first commercial Coulter Counter appeared in 1956. Automated counters made complete blood counts fast, reproducible, and cheap, and they became standard in every hospital laboratory. Quantitative measures also reshaped diagnosis: the reticulocyte count (young red cells) distinguished whether anemia was due to underproduction or to loss and destruction, and the platelet count made bleeding risk assessable. The modern flow cytometer, developed from the 1960s onward, extended counting to individual cell types labeled with fluorescent antibodies, which became the basis of immunophenotypic hematology.
Replacing Blood: Transfusion and Blood Groups
The idea of replacing lost blood is old, but safe transfusion is a twentieth-century achievement. Early attempts at animal-to-human and human-to-human transfusion in the seventeenth and nineteenth centuries often failed, and the reasons were unknown. The critical discovery was made by Karl Landsteiner in 1900–1901, when he found that human sera agglutinated the red cells of some other humans in predictable patterns, defining the ABO blood groups67. This explained why some transfusions succeeded and others caused violent reactions, and it made matched transfusion possible. The first decades of the twentieth century saw the development of citrate anticoagulation, which allowed blood to be stored rather than transfused fresh, and the establishment of blood banks during the 1930s and especially during the Second World War. The Rh factor, discovered by Landsteiner and Alexander Wiener in 1940, explained hemolytic disease of the newborn and further refined matching. Transfusion science became a discipline of its own, concerned with compatibility, storage, fractionation of plasma into products such as albumin and clotting factor concentrates, and later with screening for infectious agents such as hepatitis and HIV.
The Chemistry of Clotting: Coagulation Cascade Theory
Bleeding disorders such as hemophilia had been recognized clinically for centuries—the classic description of an inherited bleeding tendency in a family is often credited to the tenth-century physician al-Zahrawi, and the modern name comes from the nineteenth century—but the mechanism of clotting was obscure. The twentieth century turned coagulation into a biochemical system. The recognition that plasma contained multiple distinct clotting factors, each a protein that activated the next in a chain, led to the cascade or waterfall model, proposed in the 1960s by researchers including Robert Macfarlane and Earl Davie and Ratnoff. In this model, a small initial trigger sets off a sequence of enzymatic activations, each amplifying the next, ending in the conversion of fibrinogen to fibrin, the mesh that forms the clot. The model explained why deficiency of a single factor—factor VIII in hemophilia A, factor IX in hemophilia B—caused bleeding, and it gave clinicians a map for laboratory testing: the prothrombin time and the partial thromboplastin time measure different branches of the cascade. It also made possible the development of anticoagulant drugs, from heparin to warfarin, and later to direct oral anticoagulants that target specific factors. The cascade model has since been refined by the cell-based model of coagulation, which emphasizes that clotting happens on the surfaces of cells rather than in a simple test tube, but the cascade remains the organizing framework taught to every student.
The Bone Marrow as the Source
If blood cells are produced somewhere, where? The bone marrow was identified as the site of blood formation in the nineteenth century, and bone marrow examination—aspiration of marrow fluid and biopsy of marrow tissue—became a diagnostic procedure in the early twentieth century. It allowed physicians to see the factory rather than only the product: to diagnose leukemia by the presence of malignant cells in the marrow, to identify aplastic anemia as marrow failure, and to stage lymphomas and other cancers that invade the marrow. The procedure was refined with special needles and staining methods, and it remains a core skill of hematology. Its logic—that diseases of blood are diseases of the marrow—underpins much of modern hematology.
Attacking the Malignant Cell: Chemotherapy and Transplantation
The mid-twentieth century brought the first effective treatments for blood cancers. The observation during the Second World War that nitrogen mustard damaged bone marrow and lymphoid tissue led to the use of alkylating agents in lymphoma, and in 1948 Sidney Farber reported that the antifolate aminopterin produced temporary remissions in childhood acute lymphoblastic leukemia. This was a landmark: it showed that a systemic chemical could kill leukemic cells. The 1950s and 1960s saw the development of combination chemotherapy, pioneered in childhood leukemia by investigators such as Emil Freireich and colleagues at the National Cancer Institute, who showed that combining drugs with different mechanisms could cure a disease that single agents only palliated. The principle—that cancer cells can be killed faster than normal cells recover, and that combinations reduce resistance—became central to oncology.
Cure by chemotherapy alone was limited by marrow toxicity. The next step was to replace the marrow. Hematopoietic stem cell transplantation—first performed successfully in the late 1960s by E. Donnall Thomas and colleagues, who used marrow from a matched sibling to treat leukemia—allowed patients to survive otherwise lethal doses of chemotherapy and radiation. The procedure required understanding of histocompatibility (the HLA system), graft-versus-host disease, and the biology of stem cells. It has since expanded to autologous transplantation (using the patient's own cells) and to reduced-intensity conditioning, and it remains the most intensive curative option for many hematologic malignancies.
Reading the Genome and the Cell Surface
From the 1960s onward, two new ways of seeing transformed hematology. Molecular and cytogenetic hematology began with the discovery of the Philadelphia chromosome in chronic myeloid leukemia by Peter Nowell and David Hungerford in 1960—a visibly shortened chromosome in leukemic cells8. This was the first consistent chromosomal abnormality linked to a human cancer, and it eventually led to the identification of the BCR-ABL fusion gene and to imatinib, the targeted drug that revolutionized treatment of that disease. Cytogenetics—the study of chromosomes—became a routine part of leukemia diagnosis, and molecular techniques such as PCR and later next-generation sequencing allowed detection of mutations that predict prognosis and guide therapy.
In parallel, immunophenotypic hematology used antibodies against cell-surface markers to classify cells. The development of monoclonal antibody technology in the 1970s and flow cytometry made it possible to identify a cell's lineage and stage of maturation with precision. The CD (cluster of differentiation) numbering system, established through international workshops from the 1980s, gave a common language for these markers. Immunophenotyping became essential for diagnosing leukemias and lymphomas, distinguishing them from benign conditions, and monitoring minimal residual disease after treatment.
Engineering the Immune System: Cellular Immunotherapy
The most recent turning point is cellular immunotherapy: using the patient's own immune cells as drugs. The idea that the immune system can attack cancer is old, but the tools to direct it are new. Chimeric antigen receptor (CAR) T-cell therapy, in which a patient's T cells are genetically engineered to recognize a specific marker on cancer cells, produced dramatic remissions in refractory acute lymphoblastic leukemia and some lymphomas in the 2010s9. The first CAR T-cell therapy was approved by the U.S. Food and Drug Administration in 2017 for certain pediatric and young adult leukemias. This approach descends directly from the immunophenotypic and molecular understanding of cell-surface markers and from transplantation biology, and it represents a shift from killing cells with chemicals to reprogramming the immune system to do it.
Hematology Today
Contemporary hematology combines all of these strands. Diagnosis rests on automated counts, morphological review of smears, flow cytometric immunophenotyping, cytogenetics, and molecular sequencing. Treatment ranges from transfusion and anticoagulation to targeted drugs, combination chemotherapy, transplantation, and engineered cell therapies. Blood banking remains a separate but closely allied discipline. The open questions are substantial: why do some patients relapse after CAR T-cell therapy, how can transplantation be made safer and more widely available, how do clonal blood disorders that arise with age (such as clonal hematopoiesis) progress to leukemia, and how can the successes in blood cancers be extended to solid tumors. The field's history is one of learning to see blood at ever finer scales—from the humors to the cell to the chromosome to the engineered receptor—and of turning each new way of seeing into a way of treating.
References
- Hematology (introduction, Scope), Wikipedia
- Menstruation and humoral medicine, Wikipedia
- Humorism (Origin), Wikipedia
- Complete blood count (History), Wikipedia
- Anemia (History), Wikipedia
- Blood type (History), Wikipedia
- ABO blood group system, Wikipedia
- Philadelphia chromosome (History), Wikipedia
- CAR T cell (introduction, History), Wikipedia
The frameworks of Hematology
Each framework is a way of working the field has used: when it held, and the question it answers.
- 150-1800
- 1850-Present
Quantitative hematology
How many cells and how much hemoglobin are in the blood?
- 1870-Present
Morphological hematology
What do blood cells look like under the microscope?
- 1900-Present
- 1900-Present
Transfusion medicine and blood banking
How can one person's blood safely replace another's?
- 1940-Present
Bone marrow examination
What does the marrow show about a blood disease?
- 1955-Present
- 1960-Present
Molecular and cytogenetic hematology
What molecular defects cause blood diseases?
- 1964-Present
- 1968-Present
Hematopoietic stem cell transplantation
Can replacing marrow cure blood disease?
- 1975-Present
- 2011-Present
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Bone marrow examination grew out of Bone marrow as source paradigm
The doctrine that blood diseases are diseases of the marrow made marrow examination the logical diagnostic step; aspiration and biopsy needles developed in the early twentieth century turned that doctrine into a routine procedure.
Hematopoietic stem cell transplantation grew out of Bone marrow as source paradigm
The marrow-as-source paradigm implied that replacing a diseased marrow could cure blood diseases; transplantation was the therapeutic extension of that idea.
Quantitative hematology replaced Humorism
Quantitative measurement of blood cells and hemoglobin replaced humoral balance as the way to characterize blood, as counts and hemoglobinometry displaced the four-humor scheme in mid-nineteenth-century clinical practice.
Immunophenotyping grew out of Quantitative hematology
Flow cytometry, developed from the 1960s as an extension of automated counting, was applied to antibody-labeled cells, and that application became immunophenotyping.
Carried by Wallace Coulter.
Bone marrow examination influenced by Morphological hematology
Staining techniques developed for blood smears, notably Ehrlich's dye methods, were carried over to marrow aspirates, making marrow cells readable and establishing marrow examination as a diagnostic procedure.
Carried by Paul Ehrlich.
Molecular and cytogenetic hematology influenced by Morphological hematology
Morphological description of sickle cell disease in 1910 posed the question of its cause, which molecular hematology answered when the hemoglobin mutation was identified.
Carried by James Herrick.
Hematopoietic stem cell transplantation influenced by Transfusion medicine and blood banking
Blood banking supplied the transfusion support, HLA typing infrastructure, and matched-donor practice that made marrow transplantation clinically feasible.
Hematopoietic stem cell transplantation influenced by Combination chemotherapy
High-dose combination chemotherapy regimens developed for leukemia provided both the rationale and the conditioning regimens that made marrow transplantation possible.
Cellular immunotherapy influenced by Hematopoietic stem cell transplantation
Transplant experience with donor lymphocyte infusions showed that transplanted immune cells could attack leukemia, providing the clinical proof of concept for engineered cellular immunotherapy.
Cellular immunotherapy influenced by Immunophenotyping
Immunophenotyping identified the surface markers, such as CD19, that let engineers target immune cells to specific blood cancers.
Immunophenotyping influenced by Morphological hematology
Morphological naming of leukocyte lineages by staining behavior supplied the cell categories that immunophenotyping later redefined by surface markers rather than dyes.
Carried by Paul Ehrlich.
Beyond the field
Where Hematology's ideas came from in other fields, and what they led to there: the strongest 12 of 70 links.
Morphological hematology led to Lymphoma entity-based taxonomy in Hematologic Malignancies
Lymphoma entity-based taxonomy grew out of morphological hematology: the Kiel and Lukes-Collins classifications defined lymphoma entities by cytology and tissue architecture, extending the morphological tradition into a formal nosology.
Bone marrow as source paradigm influenced Hematopoietic stem-cell model in Hematologic Malignancies
The bone-marrow-as-source paradigm, the idea that marrow generates the formed elements of blood, was the direct foundation from which the hematopoietic stem-cell model was generalized.
Transfusion medicine and blood banking influenced Hemoglobinopathy Management in Pediatric Hematology And Oncology
Transfusion medicine and blood banking supplied the chronic transfusion regimens, iron monitoring and exchange transfusion techniques that became central to managing thalassemia and sickle cell disease. Modern hemoglobinopathy management is largely built around transfusion therapy developed in blood banking.
Transfusion medicine and blood banking influenced by Blood type in Immunogenetics
Landsteiner's discovery of the ABO blood groups in 1900 supplied the immunological basis that made safe transfusion and blood banking possible.
Carried by Karl Landsteiner.
Combination chemotherapy grew out of Chemotherapy in Medical Oncology
The medical oncology chemotherapy tradition supplied the single agents and dosing concepts from which multi-drug regimens were assembled in the 1950s and 1960s.
Combination chemotherapy grew out of Chemotherapy in Oncology
Combination chemotherapy grew directly out of single-agent cancer chemotherapy, generalising the cytotoxic approach by combining agents with different mechanisms and toxicities.
Combination chemotherapy influenced Survivorship and Late-Effects Medicine in Pediatric Hematology And Oncology
Combination chemotherapy regimens for childhood leukemia and lymphoma generated the survivor cohorts in which late effects were first systematically described. Survivorship medicine grew out of long-term follow-up of these treated patients.
Molecular and cytogenetic hematology influenced by Cytogenetics in Medical Genetics
General cytogenetics, especially the development of chromosome banding and the Philadelphia chromosome finding, provided the techniques and concepts that hematology adopted for leukemia diagnosis.
Carried by Peter Nowell; David Hungerford.
Molecular and cytogenetic hematology grew out of Morphological hematopathology in Hematologic Malignancies
Molecular and cytogenetic hematology grew out of morphological hematopathology, keeping its cell-based diagnostic categories while adding chromosome and gene-level analysis to them.
Molecular and cytogenetic hematology influenced Minimal Residual Disease-Guided Therapy in Pediatric Hematology And Oncology
Molecular and cytogenetic hematology supplied the assays, such as PCR for fusion transcripts and leukemia-specific markers, that made detection of minimal residual disease possible. MRD-guided therapy is built directly on these molecular detection methods.
Hematopoietic stem cell transplantation influenced by Transplantation Immunology and Histocompatibility Matching in Transplant Surgery
Transplantation immunology and histocompatibility matching, developed for kidney grafting, gave marrow transplantation its HLA typing and graft-versus-host reasoning.
Hematopoietic stem cell transplantation influenced by Hematopoietic stem-cell model in Hematologic Malignancies
The hematopoietic stem-cell model, established by marrow transplantation experiments in mice, supplied the concept of a self-renewing stem cell that made clinical marrow transplantation conceivable.

Hematology is a planet in Nousfarer
Its city has a tower for each of these 12 frameworks. Land, walk in, and climb one concept at a time.
Land on HematologyRelated fields
Fields its ideas are linked to
- Hematologic Malignancies 15 links
- Pediatric Hematology And Oncology 10 links
- Internal Medicine 5 links
- Immunogenetics 4 links
- Immunology 3 links
- Clinical Immunology 2 links
- Immunotherapy 2 links
- Tumor Immunology 2 links
- Public Health 2 links
- Oncology 2 links
- Transplant Surgery 2 links
- Cell Biology 1 link